Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2013 10:30 ET | Source: PharmaCyte Biotech, Inc.

Nuvilex Advances Company Toward Future Clinical Treatments Through Successful Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes

SILVER SPRING, Md., Nov. 8, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX) -- On Thursday, November 7, 2013, the Financial Industry Regulatory Authority, Inc. ("FINRA") halted trading in all OTC...
November 07, 2013 09:30 ET | Source: PharmaCyte Biotech, Inc.

Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Live-Cell Encapsulation Technology for Diabetes

SILVER SPRING, Md., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases,...
September 17, 2013 08:45 ET | Source: PharmaCyte Biotech, Inc.

Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials

SILVER SPRING, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX) ("Company"), an international biotechnology company providing cell and gene therapy solutions for the treatment of...
August 05, 2013 09:30 ET | Source: PharmaCyte Biotech, Inc.

Nuvilex Provides Shareholder Update

SILVER SPRING, Md., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX) (the "Company"), an international biotechnology company and provider of natural products and cell and gene therapy...
July 11, 2013 09:30 ET | Source: PharmaCyte Biotech, Inc.

Nuvilex Completes Acquisition of Exclusive Worldwide Rights to Pancreatic Cancer Treatment Technology

SILVER SPRING, Md., July 11, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), (the "Company"), an international biotechnology company and provider of natural products and cell and gene therapy...
May 09, 2013 09:30 ET | Source: PharmaCyte Biotech, Inc.

The KonLin Letter Reiterates Upside Potential of Nuvilex Technologies in May Report

SILVER SPRING, Md., May 9, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for...
March 07, 2013 09:45 ET | Source: PharmaCyte Biotech, Inc.

Nuvilex's Subsidiary to Develop "Two-Pronged" Approach to Cancer Treatment

SILVER SPRING, Md., March 7, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for...
February 27, 2013 10:10 ET | Source: PharmaCyte Biotech, Inc.

Nuvilex Focused on Positioning Subsidiary, Medical Marijuana Sciences, Inc., to be a Leading Medical Marijuana Entity by Developing Brain and Pancreatic Cancer Treatments

SILVER SPRING, Md., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for...
February 25, 2013 09:30 ET | Source: PharmaCyte Biotech, Inc.

Nuvilex's Subsidiary, Medical Marijuana Sciences, Inc., Presents Further Rationale for Use of Cannabinoids in Treatments for Pancreatic and Brain Cancers

SILVER SPRING, Md., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for...
February 20, 2013 09:45 ET | Source: PharmaCyte Biotech, Inc.

Nuvilex Reports Cannabinoid-Based Pancreatic Cancer Treatments to be Developed by Its Subsidiary, Medical Marijuana Sciences, Inc.

SILVER SPRING, Md., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for...